Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver - Results of a pilot study

Alimentary Pharmacology and Therapeutics

Volumn 23, Issue 1, 2006, Pages 121-128

  Deibert, P ^a   Schumacher, Y O ^a   Ruecker, G ^a   Opitz, O G ^a   Blum, H E ^a   Rossle M ^b   Kreisel, W ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Gastroenterology and Endocrinology Center   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; VARDENAFIL;

ADULT; ARTERY RESISTANCE; ARTICLE; BLOOD FLOWMETRY; BLOOD PRESSURE MEASUREMENT; CELIAC ARTERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; DRUG BLOOD LEVEL; DRUG EFFECT; ENZYME INHIBITION; FEMALE; HEART RATE; HEMODYNAMICS; HEPATIC ARTERY; HUMAN; LIVER BLOOD FLOW; LIVER CIRRHOSIS; MALE; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; SPLANCHNIC BLOOD FLOW;

ADULT; BLOOD FLOW VELOCITY; BLOOD PRESSURE; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMIDAZOLES; LIVER CIRCULATION; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PILOT PROJECTS; PIPERAZINES; PORTAL SYSTEM; SPLANCHNIC CIRCULATION; SULFONES; TRIAZINES;

EID: 33644912648     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02735.x     Document Type: Article

References (50)

1. Garcia-Tsao G Portal hypertension Curr Opin Gastroenterol 2005 21 313 22
2. Gines P Cardenas A Arroyo V Rodes J Management of cirrhosis and ascites N Engl J Med 2004 350 1646 54
3. Bosch J Abraldes JG Groszmann R Current management of portal hypertension J Hepatol 2003 38 Suppl. 1 S54 68
4. Bhathal PS Grossman HJ Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators J Hepatol 1985 1 325 37
5. Wiest R Groszmann RJ The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough Hepatology 2002 35 478 91
6. Shah V Lyford G Gores G Farrugia G Nitric oxide in gastrointestinal health and disease Gastroenterology 2004 126 903 13
7. Shah V Garcia-Cardena G Sessa WC Groszmann RJ The hepatic circulation in health and disease: report of a single-topic symposium Hepatology 1998 27 279 88
8. Sarela AI Mihaimeed FMA Batten JJ Davidson BR Mathie RT Hepatic and splanchnic nitric oxide activity in patients with cirrhosis Gut 1999 44 749 53
9. Wiest R Groszmann RJ Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance Semin Liver Dis 1999 19 411 26
10. Münzel T Feil R Mulsch A Lohmann SM Hofmann F Walter U Physiology and pathophysiology of vascular signaling controlled by cyclic guanosine 3′,5′-cyclic monophosphate-dependent protein kinase Circulation 2003 108 2172 83
11. Rybalkin SD Rybalkina IG Feil R Hofmann F Beavo JA Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells J Biol Chem 2002 277 3310 7
12. Maurice DH Palmer D Tilley DG et al. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system Mol Pharmacol 2003 64 533 46
13. Hofmann F The biology of cyclic GMP-dependent protein kinases J Biol Chem 2005 280 1 4
14. Rockey DC Hepatic blood flow regulation by stellate cells in normal and injured liver Semin Liver Dis 2001 21 337 49
15. Shah V Haddad FG Garcia-Cardena G Frangos JA Mennone A Groszmann RJ Sessa WC Liver sinusoidal endothelial cells are responsible for nitric oxide modulation of resistance in the hepatic sinusoids J Clin Invest 1997 100 2923 30
16. McCuskey RS Morphological mechanisms for regulating blood flow through hepatic sinusoids Liver 2000 20 3 7
17. Rockey DC Chung JJ Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension Gastroenterology 1998 114 344 51
18. Mittal MK Gupta TK Lee FY Sieber CC Groszmann RJ Nitric oxide modulates hepatic vascular tone in normal rat liver Gastroint Liver Physiol 1994 267 G416 22
19. Van de Casteele M Omasta A Janssens S et al. In vivo gene transfer of endothelial nitric oxide synthase decreases portal pressure in anaesthetised carbon tetrachloride cirrhotic rats Gut 2002 51 440 5
20. Sogni P Yang S Pilette C et al. Acute and chronic haemodynamic effects of naftazone in portal hypertensive rats Eur J Pharmacol 1998 344 37 43
21. Garcia-Tsao G Portal hypertension Curr Opin Gastroenterol 2004 20 254 63
22. Gines P Guevara M Arroyo V Rodes J Hepatorenal syndrome Lancet 2003 362 1819 27
23. de Franchis R Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension J Hepatol 2000 33 846 52
24. Angelico M Carli L Piat C et al. Isosorbide-5-mononitrate versus propranolol in the prevention of first bleeding in cirrhosis Gastroenterology 1993 104 1460 5
25. Angelico M Carli L Piat C Gentile S Capocaccia L Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis Gastroenterology 1997 113 1632 9
26. Garcia-Pagan JC Navasa M Bosch J Bru C Pizcueta P Rodes J Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis Hepatology 1990 11 230 8
27. Morillas RM Planas R Cabre E et al. Propranolol plus isosorbide-5- mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effects Hepatology 1994 20 1502 8
28. Villanueva C Balanzo J Novella MT et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding N Engl J Med 1996 334 1624 9
29. Villanueva C Minana J Ortiz J Gallego A Soriano G Torras X Sainz S Boadas J Cusso X Guarner C Balanzo J Endoscopic Ligation Compared with Combined Treatment with Nadolol and Isosorbide Mononitrate to Prevent Recurrent Variceal Bleeding N Engl J Med 2001 345 647 55
30. Fiorucci S Antonelli E Morelli A Nitric oxide and portal hypertension: a nitric oxide-releasing derivative of ursodeoxycholic acid that selectively releases nitric oxide in the liver Dig Liver Dis 2003 35 Suppl. 2 S61 9
31. Loureiro-Silva MR Cadelina GW Iwakiri Y Groszmann RJ A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats J Hepatol 2003 39 940 6
32. Groszmann RJ Wongcharatrawee S The hepatic venous pressure gradient: anything worth doing should be done right Hepatology 2004 39 280 2
33. Albillos A Perez-Paramo M Cacho G et al. Accuracy of portal and forearm blood flow measurements in the assessment of the portal pressure response to propranolol J Hepatol 1997 27 496 504
34. Haag K Rossle M Ochs A et al. Correlation of duplex sonography findings and portal pressure in 375 patients with portal hypertension Am J Roentgenol 1999 172 631 5
35. Schepke M Raab P Hoppe A Schiedermaier P Brensing KA Sauerbruch T Comparison of portal vein velocity and the hepatic venous pressure gradient in assessing the acute portal hemodynamic response to propranolol in patients with cirrhosis Am J Gastroenterol 2000 95 2905 9
36. Tasu JP Rocher L Peletier G et al. Hepatic venous pressure gradients measured by duplex ultrasound Clin Radiol 2002 57 746 52
37. Pan Z Wu XJ Li JS Liu FN Li WS Han JM Functional hepatic flow in patients with liver cirrhosis World J Gastroenterol 2004 10 915 8
38. Colle I De Vriese AS Van Vlierberghe H Lameire NH DeVos M Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis support for a risk in cirrhotic patients Liver Int 2004 24 63 68
39. Garcia N Maleknia F Mirshahi F Sanyal AJ Systemic and portal hemodynamic effects of sildenafil citrate Gastroenterology 2001 120 A-378
40. Tzathas C Christidou A Ladas SD Sildenafil (viagra) is a risk factor for acute variceal bleeding Am J Gastroenterol 2002 97 1856
41. Finley DS Lugo B Ridgway J Teng W Imagawa DK Fatal variceal rupture after sildenafil use: report of a case Curr Surg 2005 62 55 56
42. Maksan SM Ryschich E Ulger Z Gebhard MM Schmidt J Disturbance of hepatic and intestinal microcirculation in experimental liver cirrhosis World J Gastroenterol 2005 11 846 9
43. Piscaglia F Gaiani S Siringo S Gramantieri L Serra C Bolondi L Duplex-Doppler evaluation of the effects of propranolol and isosorbide-5- mononitrate on portal flow and splanchnic arterial circulation in cirrhosis Aliment Pharmacol Ther 1998 12 475 81
44. Kocakoc E Ardicoglu A Bozgeyik Z Kiris A Yuzgec V Ogur E Effects of sildenafil on major arterial blood flow using duplex sonography J Clin Ultrasound 2005 33 173 5
45. Goldstein I Lue TF Padma-Nathan H Rosen RC Steers WD Wicker PA Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group N Engl J Med 1998 338 1397 404
46. Herrmann HC Chang G Klugherz BD Mahoney PD Hemodynamic effects of sildenafil in men with severe coronary artery disease N Engl J Med 2000 342 1622 6
47. Blount MA Beasley A Zoraghi R et al. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation Mol Pharmacol 2004 66 144 52
48. Jackson G Benjamin N Jackson N Allen MJ Effects of sildenafil citrate on human hemodynamics Am J Cardiol 1999 83 13C 20C
49. Zusman RM Morales A Glasser DB Osterloh IH Overall cardiovascular profile of sildenafil citrate Am J Cardiol 1999 83 35C 44C
50. Tran D Howes LG Cardiovascular safety of sildenafil Drug Saf 2003 26 453 60